Valneva Reports 3% Revenue Growth to €174.7M for FY 2025
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy VALN?
Source: seekingalpha
- Financial Overview: Valneva reported FY 2025 revenue of €174.7 million, a 3% increase year-over-year, with product sales contributing €157.9 million; however, the net loss surged to €115.2 million from €12.2 million in 2024, indicating significant financial challenges ahead.
- Cash Flow Improvement: The year-end cash position stood at €109.7 million, bolstered by successful debt refinancing, while operating cash burn decreased to €52.9 million in 2025 from €67.2 million in 2024 and €202.7 million in 2023, reflecting effective cost management efforts.
- Future Outlook: Valneva anticipates total revenues for 2026 to range between €155 million and €170 million, with product sales expected between €145 million and €160 million, a decline attributed to the planned wind-down of third-party sales despite ongoing growth in established brands.
- R&D Investment Priority: The company will maintain a disciplined cash management approach, with further reductions in operating cash burn expected in 2026, while continuing to support strategic R&D investments, particularly with Phase 3 Lyme disease data anticipated in the first half of the year, marking a potentially transformative period for Valneva.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VALN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VALN
Wall Street analysts forecast VALN stock price to fall
2 Analyst Rating
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 10.510
Low
7.55
Averages
10.28
High
13.00
Current: 10.510
Low
7.55
Averages
10.28
High
13.00
About VALN
Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Valneva SE Reports Wider Net Loss for Fiscal 2025
- Financial Performance Decline: Valneva SE reported a net loss of €115.19 million for fiscal 2025, significantly widening from a loss of €12.25 million in 2024, primarily due to the absence of prior year gains and lower product sales, indicating severe challenges in profitability.
- Sales Decline: Product sales fell to €157.91 million in 2025 from €163.25 million in 2024, reflecting the planned wind-down of third-party sales, although proprietary product sales increased by 9% at constant exchange rates, highlighting a mixed sales performance.
- Positive Future Outlook: Valneva anticipates 2026 to be a potentially transformational year, with Phase 3 Lyme disease data expected in the first half of the year, which could significantly enhance the company's market position and investor confidence if results are favorable.
- Revenue Guidance Adjustment: The company expects total revenues for 2026 to range between €155 million and €170 million, including product sales between €145 million and €160 million, reflecting a cautious outlook on future sales amid the planned reduction of third-party sales.
See More
Valneva SE Reports 2025 Financial Results and Strategic Outlook
- Revenue Growth: Valneva SE reported total revenue of €174.7 million for 2025, a 13.7% increase from €153.7 million in 2024, reflecting strong performance in collaboration and other operating revenues, which bolsters confidence for future growth.
- Product Sales Dynamics: Product sales for 2025 amounted to €157.9 million, slightly down from €163.3 million in 2024, indicating a minor pullback following strong commercial performance in the previous year, which may affect short-term market expectations.
- Cash Flow Position: The company ended the year with a cash position of €109.7 million, supported by successful debt refinancing and a 21% reduction in operating cash burn, enhancing financial flexibility for 2026 and securing future investment opportunities.
- Vaccine Development Outlook: Valneva's Lyme disease vaccine candidate, developed in partnership with Pfizer, is expected to enter Phase 3 clinical trials in the first half of 2026, being one of the most advanced Lyme disease vaccine efforts globally, anticipated to drive long-term value for the company.
See More
Valneva Reports 3% Revenue Growth to €174.7M for FY 2025
- Financial Overview: Valneva reported FY 2025 revenue of €174.7 million, a 3% increase year-over-year, with product sales contributing €157.9 million; however, the net loss surged to €115.2 million from €12.2 million in 2024, indicating significant financial challenges ahead.
- Cash Flow Improvement: The year-end cash position stood at €109.7 million, bolstered by successful debt refinancing, while operating cash burn decreased to €52.9 million in 2025 from €67.2 million in 2024 and €202.7 million in 2023, reflecting effective cost management efforts.
- Future Outlook: Valneva anticipates total revenues for 2026 to range between €155 million and €170 million, with product sales expected between €145 million and €160 million, a decline attributed to the planned wind-down of third-party sales despite ongoing growth in established brands.
- R&D Investment Priority: The company will maintain a disciplined cash management approach, with further reductions in operating cash burn expected in 2026, while continuing to support strategic R&D investments, particularly with Phase 3 Lyme disease data anticipated in the first half of the year, marking a potentially transformative period for Valneva.
See More
Zevra Therapeutics Reports Strong Q4 Earnings, Shares Surge
- Earnings Beat: Zevra Therapeutics reported Q4 earnings of $0.19 per share, significantly surpassing the analyst consensus of $0.05, indicating a notable improvement in profitability and boosting investor confidence.
- Sales Growth: The company achieved quarterly sales of $34.125 million, exceeding the analyst estimate of $28.051 million, reflecting strong product demand and solid market performance, which may drive future growth potential.
- Stock Surge: Following the earnings report, Zevra Therapeutics shares jumped 17.2% to $10.70 in pre-market trading, indicating a positive market reaction to the company's performance and potentially attracting more investor interest.
- Optimistic Market Outlook: This earnings beat not only enhances the company's short-term stock price but may also lay a foundation for long-term development, strengthening market confidence in its future growth prospects.
See More
Latham Group Shares Surge After Strong Q4 Results
- Strong Earnings Report: Latham Group reported a fourth-quarter loss of 6 cents per share, outperforming analyst expectations of a 10-cent loss, indicating improvements in cost control and operational efficiency.
- Sales Exceed Expectations: The company achieved quarterly sales of $99.950 million, surpassing the analyst consensus estimate of $96.786 million, reflecting strong market demand and robust product performance, which bolstered investor confidence.
- Significant Stock Surge: Following the positive earnings report, Latham Group's shares jumped 25.7% to $8.10 on Wednesday, reflecting market optimism regarding the company's future growth potential.
- Positive Future Outlook: Latham Group issued FY26 sales guidance above estimates, further solidifying investor confidence in the company's long-term growth trajectory.
See More
Valneva Management to Attend Investor Conferences
- Investor Conference Schedule: Valneva SE will participate in the TD Cowen 46th Annual Health Care Conference on March 4, 2026, in Boston, where CEO Thomas Lingelbach and CFO Peter Buhler will discuss key value drivers and upcoming catalysts, which is expected to positively impact the company's stock price.
- Vaccine Development Progress: The Phase 3 data for Valneva's Lyme disease vaccine candidate VLA15 is anticipated to be reported by partner Pfizer in the first half of 2026, a development that will lay the groundwork for the company's future market performance and boost investor confidence.
- Multiple Meeting Arrangements: In addition to the Boston conference, Valneva will also meet with investors at the Jefferies Biotech on the Beach Summit in Miami on March 10 and the Van Lanschot Kempen Life Sciences Conference in Amsterdam on April 15, further enhancing investor engagement.
- Vaccine Market Positioning: Valneva focuses on developing prophylactic vaccines for unmet medical needs, currently marketing three proprietary travel vaccines, and with the growth of its commercial business, it is expected to provide funding for the continued advancement of its vaccine pipeline, strengthening the company's competitive position in the vaccine market.
See More
Valneva SE Reports Wider Net Loss for Fiscal 2025
- Financial Performance Decline: Valneva SE reported a net loss of €115.19 million for fiscal 2025, significantly widening from a loss of €12.25 million in 2024, primarily due to the absence of prior year gains and lower product sales, indicating severe challenges in profitability.
- Sales Decline: Product sales fell to €157.91 million in 2025 from €163.25 million in 2024, reflecting the planned wind-down of third-party sales, although proprietary product sales increased by 9% at constant exchange rates, highlighting a mixed sales performance.
- Positive Future Outlook: Valneva anticipates 2026 to be a potentially transformational year, with Phase 3 Lyme disease data expected in the first half of the year, which could significantly enhance the company's market position and investor confidence if results are favorable.
- Revenue Guidance Adjustment: The company expects total revenues for 2026 to range between €155 million and €170 million, including product sales between €145 million and €160 million, reflecting a cautious outlook on future sales amid the planned reduction of third-party sales.
See More
Valneva SE Reports 2025 Financial Results and Strategic Outlook
- Revenue Growth: Valneva SE reported total revenue of €174.7 million for 2025, a 13.7% increase from €153.7 million in 2024, reflecting strong performance in collaboration and other operating revenues, which bolsters confidence for future growth.
- Product Sales Dynamics: Product sales for 2025 amounted to €157.9 million, slightly down from €163.3 million in 2024, indicating a minor pullback following strong commercial performance in the previous year, which may affect short-term market expectations.
- Cash Flow Position: The company ended the year with a cash position of €109.7 million, supported by successful debt refinancing and a 21% reduction in operating cash burn, enhancing financial flexibility for 2026 and securing future investment opportunities.
- Vaccine Development Outlook: Valneva's Lyme disease vaccine candidate, developed in partnership with Pfizer, is expected to enter Phase 3 clinical trials in the first half of 2026, being one of the most advanced Lyme disease vaccine efforts globally, anticipated to drive long-term value for the company.
See More
Valneva Reports 3% Revenue Growth to €174.7M for FY 2025
- Financial Overview: Valneva reported FY 2025 revenue of €174.7 million, a 3% increase year-over-year, with product sales contributing €157.9 million; however, the net loss surged to €115.2 million from €12.2 million in 2024, indicating significant financial challenges ahead.
- Cash Flow Improvement: The year-end cash position stood at €109.7 million, bolstered by successful debt refinancing, while operating cash burn decreased to €52.9 million in 2025 from €67.2 million in 2024 and €202.7 million in 2023, reflecting effective cost management efforts.
- Future Outlook: Valneva anticipates total revenues for 2026 to range between €155 million and €170 million, with product sales expected between €145 million and €160 million, a decline attributed to the planned wind-down of third-party sales despite ongoing growth in established brands.
- R&D Investment Priority: The company will maintain a disciplined cash management approach, with further reductions in operating cash burn expected in 2026, while continuing to support strategic R&D investments, particularly with Phase 3 Lyme disease data anticipated in the first half of the year, marking a potentially transformative period for Valneva.
See More
Zevra Therapeutics Reports Strong Q4 Earnings, Shares Surge
- Earnings Beat: Zevra Therapeutics reported Q4 earnings of $0.19 per share, significantly surpassing the analyst consensus of $0.05, indicating a notable improvement in profitability and boosting investor confidence.
- Sales Growth: The company achieved quarterly sales of $34.125 million, exceeding the analyst estimate of $28.051 million, reflecting strong product demand and solid market performance, which may drive future growth potential.
- Stock Surge: Following the earnings report, Zevra Therapeutics shares jumped 17.2% to $10.70 in pre-market trading, indicating a positive market reaction to the company's performance and potentially attracting more investor interest.
- Optimistic Market Outlook: This earnings beat not only enhances the company's short-term stock price but may also lay a foundation for long-term development, strengthening market confidence in its future growth prospects.
See More
Latham Group Shares Surge After Strong Q4 Results
- Strong Earnings Report: Latham Group reported a fourth-quarter loss of 6 cents per share, outperforming analyst expectations of a 10-cent loss, indicating improvements in cost control and operational efficiency.
- Sales Exceed Expectations: The company achieved quarterly sales of $99.950 million, surpassing the analyst consensus estimate of $96.786 million, reflecting strong market demand and robust product performance, which bolstered investor confidence.
- Significant Stock Surge: Following the positive earnings report, Latham Group's shares jumped 25.7% to $8.10 on Wednesday, reflecting market optimism regarding the company's future growth potential.
- Positive Future Outlook: Latham Group issued FY26 sales guidance above estimates, further solidifying investor confidence in the company's long-term growth trajectory.
See More
Valneva Management to Attend Investor Conferences
- Investor Conference Schedule: Valneva SE will participate in the TD Cowen 46th Annual Health Care Conference on March 4, 2026, in Boston, where CEO Thomas Lingelbach and CFO Peter Buhler will discuss key value drivers and upcoming catalysts, which is expected to positively impact the company's stock price.
- Vaccine Development Progress: The Phase 3 data for Valneva's Lyme disease vaccine candidate VLA15 is anticipated to be reported by partner Pfizer in the first half of 2026, a development that will lay the groundwork for the company's future market performance and boost investor confidence.
- Multiple Meeting Arrangements: In addition to the Boston conference, Valneva will also meet with investors at the Jefferies Biotech on the Beach Summit in Miami on March 10 and the Van Lanschot Kempen Life Sciences Conference in Amsterdam on April 15, further enhancing investor engagement.
- Vaccine Market Positioning: Valneva focuses on developing prophylactic vaccines for unmet medical needs, currently marketing three proprietary travel vaccines, and with the growth of its commercial business, it is expected to provide funding for the continued advancement of its vaccine pipeline, strengthening the company's competitive position in the vaccine market.
See More
